Cardiff Oncology, Inc.

Equities

CRDF

US14147L1089

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 18/07/2024 am IST			5-day change	1st Jan Change
2.54 ^USD	-2.31%		+14.93%	+71.62%

01/07	Cardiff Oncology, Inc.(NasdaqCM:CRDF) added to Russell Small Cap Comp Value Index	CI
01/07	Cardiff Oncology, Inc.(NasdaqCM:CRDF) added to Russell Small Cap Completeness Index	CI

Cardiff Oncology : Corporate Presentation - January 2023

January 05, 2023 at 05:18 am IST

Company Overview

The Onvansertib Opportunity

Our Drug: Onvansertib

WHAT

WHERE

WHY

Our Drug: Onvansertib

PROPERTIES	SPECIFICITY
•
•
•

Targets with		Targets without
oncogenic		oncogenic
alterations		alterations

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

Original Link
Original Document
Permalink

Disclaimer

Cardiff Oncology Inc. published this content on 04 January 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 January 2023 23:47:01 UTC.

Latest news about Cardiff Oncology, Inc.

Cardiff Oncology, Inc.(NasdaqCM:CRDF) added to Russell Small Cap Comp Value Index	01/07	CI
Cardiff Oncology, Inc.(NasdaqCM:CRDF) added to Russell Small Cap Completeness Index	01/07	CI
Cardiff Oncology, Inc.(NasdaqCM:CRDF) added to Russell 2000 Index	01/07	CI
Cardiff Oncology, Inc.(NasdaqCM:CRDF) added to Russell 3000E Index	01/07	CI
Cardiff Oncology, Inc.(NasdaqCM:CRDF) added to Russell 3000 Growth Index	01/07	CI
Cardiff Oncology, Inc.(NasdaqCM:CRDF) added to Russell 2500 Value Index	01/07	CI
Cardiff Oncology, Inc.(NasdaqCM:CRDF) added to Russell Microcap Growth Index	01/07	CI
Cardiff Oncology, Inc.(NasdaqCM:CRDF) added to Russell 3000 Value Index	01/07	CI
Cardiff Oncology, Inc.(NasdaqCM:CRDF) added to Russell 2000 Value Index	01/07	CI
Cardiff Oncology, Inc.(NasdaqCM:CRDF) added to Russell 3000E Growth Index	01/07	CI
Cardiff Oncology, Inc.(NasdaqCM:CRDF) added to Russell 2000 Growth Index	01/07	CI
Cardiff Oncology, Inc.(NasdaqCM:CRDF) added to Russell 2000 Dynamic Index	01/07	CI
Cardiff Oncology, Inc.(NasdaqCM:CRDF) added to Russell 2500 Growth Index	01/07	CI
Cardiff Oncology, Inc.(NasdaqCM:CRDF) added to Russell Small Cap Comp Growth Index	01/07	CI
Cardiff Oncology, Inc.(NasdaqCM:CRDF) added to Russell 2500 Index	01/07	CI
Cardiff Oncology, Inc.(NasdaqCM:CRDF) added to Russell 3000 Index	01/07	CI
Cardiff Oncology, Inc.(NasdaqCM:CRDF) added to Russell 3000E Value Index	01/07	CI
Transcript : Cardiff Oncology, Inc., Q1 2024 Earnings Call, May 02, 2024	03/05
Cardiff Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	03/05	CI
Cardiff Oncology Presents Novel Preclinical Data At Aacr Annual Meeting 2024 That Supports Ongoing First-Line Ras-Mutated Mcrc Clinical Study	09/04	CI
HC Wainwright Adjusts Price Target on Cardiff Oncology to $14 From $12, Keeps Buy Rating	06/03	MT
Sector Update: Health Care Stocks Rising Late Afternoon	02/03	MT
Sector Update: Health Care	02/03	MT
Cardiff Oncology Shares Jump, Discontinued Cancer Treatment Trial Shows Efficacy	02/03	MT
Piper Sandler Adjusts Price Target on Cardiff Oncology to $7 From $5, Maintains Overweight Rating	01/03	MT

Chart Cardiff Oncology, Inc.

Duration

Period

More charts

Company Profile

Cardiff Oncology, Inc. is a clinical-stage biotechnology company. It is leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the unmet medical need. It is focused on clinical programs in indications, such as RAS-mutated metastatic colorectal cancer (mCRC), and in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC). Its lead drug candidate, Onvansertib, is an oral, small molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life. It has five ongoing and planned clinical trials of onvansertib: one trial (CRDF-004) in first-line treatment in patients with RAS-mutated mCRC, one trial (CRDF-001) in second-line treatment in patients with mPDAC, and three investigator-initiated trials in first line mPDAC, relapsed SCLC and unresectable locally advanced or metastatic TNBC.

Sector

Biotechnology & Medical Research

Calendar

08/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Cardiff Oncology, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.54 USD

Average target price

9.833 USD

Spread / Average Target

+287.14%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CARDIFF ONCOLOGY, INC.	+71.62%	11Cr
MODERNA, INC.	+24.74%	4.75TCr
IQVIA HOLDINGS INC.	-0.47%	4.2TCr
LONZA GROUP AG	+48.77%	4.16TCr
ALNYLAM PHARMACEUTICALS, INC.	+25.40%	3.04TCr
ICON PUBLIC LIMITED COMPANY	+17.96%	2.76TCr
CELLTRION, INC.	-4.47%	2.87TCr
UNITED THERAPEUTICS CORPORATION	+50.73%	1.47TCr
MEDPACE HOLDINGS, INC.	+42.56%	1.35TCr
BIO-TECHNE CORPORATION	+1.46%	1.23TCr

Other Biotechnology & Medical Research